证券代码：000516 证券简称：国际医学 公告编号：2025-049 西安国际医学投资股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 西安国际医学投资股份有限公司（以下简称"公司"）近日接到控 股股东陕西世纪新元商业管理有限公司（以下简称"世纪新元"）的通 知，世纪新元使用其持有的本公司部分股份与长安国际信托股份有限公 司进行的融资类质押已办理了解除质押手续，具体事项如下： 三、其他说明 截至本公告日，公司控股股东世纪新元及其一致行动人质押的股份 不存在平仓风险，不会导致公司实际控制权发生变更，不会对公司的经 营成果和财务状况产生影响。公司将持续关注股东股份质押及质押风险 情况，及时履行信息披露义务，敬请广大投资者注意投资风险。 四、备查文件 二、控股股东股份累计质押的基本情况 截至公告披露日，世纪新元及其一致行动人所持质押股份情况如下： | 股 | 持股数量 | 持股 | 本次解 | 本次解 | 占其 | 占公 | 已质押股份 | 未质押股份 | | --- | --- | --- | --- | --- ...

Core Viewpoint - The announcement indicates that the controlling shareholder, Century Xinyuan, will release a pledge of 34.0642 million shares, which represents 5.53% of its holdings and 1.52% of the company's total share capital, on November 4 [1] Summary by Relevant Sections - **Share Pledge Details** - Century Xinyuan will handle the release of the pledged shares on November 4, with the initial pledge date being February 26, 2024 [1] - As of the announcement date, the total pledged shares by Century Xinyuan and its concerted parties have decreased to 474 million shares, accounting for 65.99% of their holdings and 21.18% of the company's total share capital [1] - **Impact on Company** - The controlling shareholder's pledged shares do not pose a risk of forced liquidation and will not affect the company's control, operations, or financial status [1]

Core Viewpoint - International Medical (000516) has shown a decline in stock price and financial performance, indicating potential challenges in the healthcare service sector [1][3]. Financial Performance - As of November 4, 2025, the stock closed at 4.78 yuan, down 0.42% with a trading volume of 139,000 hands and a transaction amount of 66.53 million yuan [1]. - For the first three quarters of 2025, the company's main revenue was 2.995 billion yuan, a year-on-year decrease of 16.94%, and the net profit attributable to shareholders was -294 million yuan, down 38.45% [3]. - The third quarter alone saw a main revenue of 961 million yuan, a decline of 18.95%, and a net profit of -129 million yuan, a staggering drop of 234.24% [3]. Market Position - The total market value of International Medical is 10.702 billion yuan, ranking 12th in the healthcare service industry, which has an average market value of 19.659 billion yuan [3]. - The company has a net asset value of 3.054 billion yuan, ranking 14th in the industry [3]. - The company's gross margin is 6.59%, significantly lower than the industry average of 35.56%, placing it 41st in the industry ranking [3]. Investment Sentiment - In the last 90 days, two institutions have provided ratings for the stock, with one giving a buy rating and another an increase rating [4].

Core Viewpoint - International Medical stated that the pledged financing by its controlling shareholder and concerted parties does not involve meeting the operational needs of the listed company, and there is currently no risk of forced liquidation of the pledged shares [2] Group 1 - The pledged shares do not have a substantial impact on the company's operations and governance [2] - The controlling shareholder and concerted parties have a good credit status and strong repayment capability, indicating that the pledge risk is manageable [2] - The pledge rate of the controlling shareholder and concerted parties may change due to pledging and unpledging activities [2]

Group 1 - The stock price of International Medical (000516) closed at 4.8 yuan as of October 31, 2025, down 1.44% from 4.87 yuan the previous week, with a market cap of 10.747 billion yuan, ranking 17th in the medical services sector and 1766th in the A-share market [1] - The highest intraday price reached 4.92 yuan on October 27, 2025, while the lowest intraday price was 4.74 yuan on October 30, 2025, marking a near one-year low [1] Group 2 - As of September 30, 2025, the number of shareholders was 103,200, a decrease of 7,250 or 6.56% from June 30, 2025, with an average shareholding of 21,700 shares per account [2][4] - The average market value per account was 105,200 yuan [2] Group 3 - The financial report for the first three quarters of 2025 shows a total revenue of 2.995 billion yuan, a year-on-year decrease of 16.94%, and a net profit attributable to shareholders of -294 million yuan, down 38.45% year-on-year [3] - The third quarter alone reported a revenue of 961 million yuan, a decline of 18.95% year-on-year, with a net profit of -129 million yuan, a significant drop of 234.24% year-on-year [3] - The company reported a debt ratio of 68.8%, investment income of 20.7586 million yuan, financial expenses of 111 million yuan, and a gross profit margin of 6.59% [3]

Summary of the Conference Call Company and Industry - **Company**: International Medical - **Industry**: Healthcare and Medical Services Key Points and Arguments 1. Innovation and Talent Development - The establishment and application of an innovative treatment system for cervical spine diseases has won the first prize for scientific and technological progress in Shaanxi Province - Continuous improvement in the talent structure within the company's medical institutions, with notable achievements including: - 4 new doctoral and master's supervisors - 87 doctoral and master's degree holders - 21 mid-to-senior title holders - The clinical research capabilities have been strengthened, with 17 provincial-level academic conferences hosted and over 100 academic papers published, including 14 SCI papers [1][2] 2. Operational Performance - In the first three quarters of 2025, the total number of outpatient and emergency services reached 1.97 million, a year-on-year increase of 4.03% - Inpatient services totaled 145,900, a decrease of 3.88% year-on-year - Revenue for the first three quarters was approximately 2.995 billion yuan, a decrease of 16.94% year-on-year, with a net profit attributable to shareholders of negative 200 million yuan, down 38.45% [2][3] 3. Financial Metrics - In Q3 2025, revenue was approximately 900 million yuan, a decrease of 18.95% year-on-year, with a net profit of negative 100 million yuan, down 234% - Operating cash flow for the first three quarters was 921 million yuan, an increase of 47.67% year-on-year, indicating stable medical business returns [3][4] 4. Cost Management - Management expense ratio decreased by 0.54 percentage points to 10.99% - Financial expense ratio decreased by 0.07 percentage points to 3.43% [3][4] 5. Hospital Performance - High-tech hospital outpatient services reached 864,200, a year-on-year increase of 1.33%, while inpatient services decreased by 5.73% - The central hospital saw outpatient services of 1.11 million, a year-on-year increase of 6.24%, but inpatient services decreased by 3.01% [4][5] 6. Impact of Medical Insurance Policy - The decline in revenue and profit in Q3 was significantly influenced by the medical insurance policy reform, which required hospitals to return excess funds from the previous year, impacting income and profit directly [12][15] 7. Future Outlook - The fourth quarter is expected to be a peak season for medical services, with a focus on cost control and efficiency improvement - The company aims to enhance medical quality and patient experience while expanding service scale and improving profitability [7][8] 8. New Business Developments - The company is expanding into consumer-oriented medical services, with notable growth in areas such as elderly care and aesthetic medicine - The proton therapy project is seen as a competitive advantage, with installation and testing progressing well [29][49] 9. Digital Asset Strategy - The company has registered its medical data assets on a trading platform, signaling readiness for potential collaborations and transactions in the future [55][58] 10. Management's Commitment - The management emphasizes a commitment to deepening core business operations and enhancing overall value accumulation while adapting to industry changes and policies [61][62] Other Important but Overlooked Content - The company has a strong focus on integrating technology and digital solutions to improve operational efficiency and patient care - The management is optimistic about the potential for future growth in the healthcare sector, despite current challenges [56][60]

Group 1: Company Overview and Performance - The company has solidified its internal capabilities and accelerated the development of its medical business in response to healthcare payment policy reforms in 2025 [1][2] - The total outpatient and emergency service volume reached 1.9751 million visits in the first three quarters, a year-on-year increase of 4.03% [2] - The company reported a total revenue of CNY 2,995.44 million, a decrease of 16.94% year-on-year, with a net profit attributable to shareholders of CNY -293.66 million, down 38.45% [2][3] Group 2: Research and Development - The company organized or hosted 17 provincial-level academic conferences and published 100 academic papers, including 14 in SCI journals [2] - The company has initiated 24 clinical trials for drugs and 3 for medical devices, further enhancing its research capabilities [2] Group 3: Hospital Performance - The High-tech Hospital reported 864,200 outpatient visits, a 1.33% increase, while inpatient services decreased by 5.73% [3] - The Central Hospital achieved 1,110,900 outpatient visits, a 6.24% increase, but saw a 3.01% decrease in inpatient services [3] Group 4: Financial Management - The company’s operating cash flow net amount was CNY 921.00 million, a 47.67% increase compared to the same period last year, indicating stable medical business returns [2] - Cost control measures have shown initial results, with management expense ratio at 10.99%, down 0.54 percentage points year-on-year [2][3] Group 5: Future Outlook - The company aims to enhance medical quality and service experience while optimizing patient service systems in the upcoming fourth quarter [4] - The establishment of a senior care facility is part of the company's strategy to integrate medical and elderly care services [4]

Core Insights - International Medicine (000516.SZ) reported its Q3 2025 results on October 30, 2025, highlighting significant institutional investment activity [1] Institutional Holdings - As of October 29, 2025, six institutional investors disclosed holdings in International Medicine A-shares, totaling 754 million shares, which represents 33.67% of the company's total equity [1] - The institutional holding percentage increased by 0.45 percentage points compared to the previous quarter [1] Public Fund Activity - In this reporting period, 16 public funds were disclosed, including Jin Ying Theme Advantage Mixed, Huatai-PB Healthcare A, Guotai Rongan Multi-Strategy Flexible Allocation Mixed A, Penghua Healthcare Stocks, and Penghua Pension Industry Stocks [1] Foreign Investment - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings, contributing an increase of 0.52% compared to the previous period [1]

Core Viewpoint - The company reported a significant decrease in net profit and various financial metrics for the third quarter, primarily due to changes in healthcare policies affecting revenue from subsidiaries [6]. Financial Data Summary - Net profit attributable to shareholders decreased by 38.45% compared to the same period last year, mainly due to reduced revenue from subsidiaries affected by dynamic adjustments in healthcare policies [6]. - Cash and cash equivalents decreased by 43.94% compared to the end of the previous year, primarily due to debt repayments by a subsidiary [6]. - Trading financial assets decreased by 84.51%, while investment income increased by 2,167.76% due to gains from the disposal of equity investment tools [6]. - Sales expenses increased by 78.56%, attributed to higher promotional costs [6]. - Credit impairment losses decreased by 269.05%, as a result of reduced provisions after the recovery of receivables [6]. - Net cash flow from operating activities increased by 47.67%, influenced by reduced cash payments for goods and services [6]. - Net cash flow from investing activities increased by 63.77%, due to decreased cash payments for fixed assets and other long-term assets [6]. - Net cash flow from financing activities decreased by 47.05%, primarily due to increased cash payments for debt repayments [6]. Shareholder Information - The company confirmed that there were no changes in the number of shareholders or significant shareholders participating in the securities lending business [7]. Board Meeting Resolutions - The board of directors approved the third quarter report with unanimous consent [11]. - Several amendments to internal management systems were approved, including the external information reporting and investor relations management systems [11][13][14].

Group 1 - The core point of the article is that International Medical (SZ 000516) reported a significant decline in its third-quarter performance for 2025, with revenue dropping by 16.94% year-on-year to approximately 2.995 billion yuan, and a net loss attributable to shareholders of about 294 million yuan, resulting in a basic loss per share of 0.1302 yuan [1]. Group 2 - As of the report, the market capitalization of International Medical is 10.8 billion yuan [2].